Ozempic is an FDA-approved medication for people who have type 2 diabetes. It’s often prescribed “off-label” for weight loss ...

NVO submits higher-dose Wegovy to EMA, aiming for greater weight loss and stronger defense against rivals in the obesity ...

CHMP recommends approval of Novo Nordisk’s Ozempic for peripheral arterial disease: Bagsværd, Denmark Wednesday, June 25, 2025, 15:00 Hrs [IST] Novo Nordisk, a leading global h ...

There’s no such thing as "natural Ozempic." While supplements like psyllium, berberine, and glucomannan are paraded as ...

NEW YORK CITY, NY / ACCESS Newswire / July 9, 2025 / Semaglutide is making waves as the powerhouse ingredient in Ozempic and ...

Ozempic ® (semaglutide) injection 0.25 mg, 0.5 mg, 1.0 mg or 2.0 mg is a once-weekly GLP-1 RA indicated, along with diet and exercise, to improve blood sugar (glucose) in adults with type 2 ...

CHMP recommends a label update for Novo Nordisk's Ozempic after the STRIDE study shows walking improvements in T2D patients with PAD.

A once-weekly injection of Wegovy® has become available in Singapore, marking the latest step in managing obesity as a ...

India is among the top two countries in terms of type 2 diabetes cases and third in terms of obesity; hence, the need for ...

Ozempic ® (semaglutide) injection 0.25 mg, 0.5 mg, 1.0 mg or 2.0 mg is a once-weekly GLP-1 RA indicated, along with diet and exercise, to improve blood sugar (glucose) in adults with type 2 diabetes ...

CHICAGO -- Semaglutide (Ozempic) reduced glucose levels and weight among patients with type 1 diabetes and obesity, a randomized trial showed.